Tirzepatide is the newer of the two molecules used for weight management and the one people increasingly ask for by name. It acts on two gut hormones rather than one, and in direct comparison it produced greater average weight loss than semaglutide.
Semaglutide mimics GLP-1. Tirzepatide mimics GLP-1 and also GIP, a second gut hormone thought to affect how the body handles sugar and fat alongside its effect on appetite.
In practice patients describe the appetite effect as similar in kind and stronger in degree. The trial data supports that: in head-to-head comparison tirzepatide produced a greater average reduction in body weight.
It is not automatically the better choice. Tolerance varies between people more than between molecules, and cost, coverage and availability all bear on which one you can actually stay on. See Semaglutide vs tirzepatide, How GLP-1 medications work and Weight loss timeline for the rest of it.
Dual action
Dosing
The tirzepatide dose schedule, step by step
Start low
As with any GLP-1, the opening dose is about tolerance. It is not expected to do much beyond letting your body adjust.
Increase on schedule
Steps at set intervals, usually every four weeks, conditional on the current dose being tolerated.
Eating adjusts too
The appetite effect tends to be pronounced. Smaller, more frequent, protein-forward meals are what most people settle into.
Find the maintenance dose
The aim is the lowest dose that holds the effect, not the maximum on the label.
Who it suits
Who is a candidate for tirzepatide
The thresholds are the same as for semaglutide: BMI 30 and above, or 27 and above with a documented weight-related condition. The exclusions are also broadly the same, including thyroid cancer history and pregnancy.
It is often considered where semaglutide has plateaued or was not tolerated, and switching between the two is a normal clinical move rather than starting again from nothing. Related reading: Who should not take it, Common side effects and Medication cost.
BMI 30, or 27 with conditionThreshold
After a plateauOften used
As for semaglutideExclusions
Related
Related weight loss medication pages
The brands tirzepatide is sold under, and the molecule it is compared with.
How it differs, whether it is stronger, and whether you can switch to it.
In head-to-head trial data it produced greater average weight loss. Averages are not predictions, and the molecule you tolerate and stay on will out-perform a statistically superior one you stop early.
Yes, and it is common where results have plateaued or side effects were not manageable. The switch involves a fresh titration rather than matching the previous dose.
Tirzepatide is the molecule. Mounjaro is a brand containing it, approved for type 2 diabetes. Zepbound is another brand containing the same molecule, approved for weight management.
The profile is broadly similar and digestive in nature. Individual tolerance varies more than the molecules do, which is why the titration schedule matters more than the choice between them.
Not currently. Tirzepatide is a weekly injection. The oral option available is a semaglutide tablet, which is a different molecule.
